A detailed history of Charles Schwab Investment Management Inc transactions in Erasca, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,723,630 shares of ERAS stock, worth $5.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,723,630
Previous 1,333,421 29.26%
Holding current value
$5.03 Million
Previous $3.15 Million 49.55%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$2.17 - $3.28 $846,753 - $1.28 Million
390,209 Added 29.26%
1,723,630 $4.71 Million
Q2 2024

Aug 12, 2024

BUY
$1.79 - $2.63 $1.2 Million - $1.76 Million
669,551 Added 100.86%
1,333,421 $3.15 Million
Q1 2024

May 08, 2024

BUY
$1.67 - $2.55 $22,937 - $35,024
13,735 Added 2.11%
663,870 $1.37 Million
Q4 2023

Feb 06, 2024

BUY
$1.67 - $2.49 $14,188 - $21,155
8,496 Added 1.32%
650,135 $1.38 Million
Q3 2023

Nov 08, 2023

BUY
$1.97 - $2.91 $120,053 - $177,338
60,941 Added 10.49%
641,639 $1.26 Million
Q2 2023

Aug 09, 2023

BUY
$2.57 - $3.3 $81,237 - $104,313
31,610 Added 5.76%
580,698 $1.6 Million
Q1 2023

May 11, 2023

BUY
$2.74 - $4.44 $260,524 - $422,164
95,082 Added 20.94%
549,088 $1.65 Million
Q4 2022

Feb 13, 2023

BUY
$3.89 - $8.57 $24,238 - $53,399
6,231 Added 1.39%
454,006 $1.96 Million
Q3 2022

Nov 14, 2022

BUY
$5.82 - $10.68 $1.28 Million - $2.35 Million
220,194 Added 96.75%
447,775 $3.49 Million
Q2 2022

Aug 15, 2022

SELL
$4.58 - $8.72 $56,137 - $106,881
-12,257 Reduced 5.11%
227,581 $1.27 Million
Q1 2022

May 13, 2022

BUY
$8.6 - $15.48 $854,083 - $1.54 Million
99,312 Added 70.67%
239,838 $2.06 Million
Q4 2021

Feb 11, 2022

BUY
$12.51 - $22.75 $89,208 - $162,230
7,131 Added 5.35%
140,526 $2.19 Million
Q3 2021

Nov 16, 2021

BUY
$17.43 - $24.34 $2.33 Million - $3.25 Million
133,395 New
133,395 $2.83 Million

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $357M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.